Literature DB >> 2655856

Measuring quality of life in clinical trials: a taxonomy and review.

G H Guyatt1, S J Veldhuyzen Van Zanten, D H Feeny, D L Patrick.   

Abstract

Measurement of quality of life is becoming increasingly relevant to controlled clinical trials. Two basic types of instrument are available: generic instruments, which include health profiles and utility measurements based on the patient's preferences in regard to treatment and outcome; and specific instruments, which focus on problems associated with individual diseases, patient groups or areas of function. The two approaches are not mutually exclusive; each has its strengths and weaknesses and may be suitable under different circumstances. We surveyed 75 randomized trials published in three medical journals in 1986 and categorized them according to the importance of quality of life as a measure of outcome and the extent to which quality of life was actually measured. Although a number of the investigators used quality-of-life instruments in a sophisticated manner, in only 10 of 55 trials in which the measurement had been judged to be crucial or important were instruments with established validity and responsiveness used. We conclude that although accurate measurement of quality of life in randomized trials is now feasible it is still not widely done. Using the framework we have outlined, investigators can choose generic or specific instruments according to the purpose and the focus of their trial.

Entities:  

Mesh:

Year:  1989        PMID: 2655856      PMCID: PMC1269981     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  41 in total

1.  Standards for the use of ordinal scales in clinical trials.

Authors:  C R MacKenzie; M E Charlson
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

2.  A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial.

Authors:  J H Hoofnagle; G L Davis; S C Pappas; R G Hanson; M Peters; M I Avigan; J G Waggoner; E A Jones; L B Seeff
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

3.  Measuring disease-specific quality of life in clinical trials.

Authors:  G H Guyatt; C Bombardier; P X Tugwell
Journal:  CMAJ       Date:  1986-04-15       Impact factor: 8.262

4.  Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research.

Authors:  M H Liang; M G Larson; K E Cullen; J A Schwartz
Journal:  Arthritis Rheum       Date:  1985-05

5.  A measure of quality of life for clinical trials in chronic lung disease.

Authors:  G H Guyatt; L B Berman; M Townsend; S O Pugsley; L W Chambers
Journal:  Thorax       Date:  1987-10       Impact factor: 9.139

6.  Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine.

Authors:  D H Shepp; P S Dandliker; J D Meyers
Journal:  N Engl J Med       Date:  1986-01-23       Impact factor: 91.245

7.  The effects of antihypertensive therapy on the quality of life.

Authors:  S H Croog; S Levine; M A Testa; B Brown; C J Bulpitt; C D Jenkins; G L Klerman; G H Williams
Journal:  N Engl J Med       Date:  1986-06-26       Impact factor: 91.245

8.  Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.

Authors:  R T Mitsuyasu; R E Champlin; R P Gale; W G Ho; C Lenarsky; D Winston; M Selch; R Elashoff; J V Giorgi; J Wells
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

9.  Lassa fever. Effective therapy with ribavirin.

Authors:  J B McCormick; I J King; P A Webb; C L Scribner; R B Craven; K M Johnson; L H Elliott; R Belmont-Williams
Journal:  N Engl J Med       Date:  1986-01-02       Impact factor: 91.245

10.  Can the Sickness Impact Profile measure change? An example of scale assessment.

Authors:  C R MacKenzie; M E Charlson; D DiGioia; K Kelley
Journal:  J Chronic Dis       Date:  1986
View more
  62 in total

Review 1.  Quality-of-life assessment in comparative therapeutic trials and causal structure considerations in peripheral occlusive arterial disease.

Authors:  P Lehert
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Design of treatment trials for functional gastrointestinal disorders.

Authors:  S J Veldhuyzen van Zanten; N J Talley; P Bytzer; K B Klein; P J Whorwell; A R Zinsmeister
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

3.  A method to select an instrument for measurement of HR-QOL for cross-cultural adaptation applied to dermatology.

Authors:  A G de Tiedra; J Mercadal; X Badía; J M Mascaró; R Lozano
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

4.  Quality of life after epilepsy surgery.

Authors:  M W Kellett; D F Smith; G A Baker; D W Chadwick
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

Review 5.  Measuring the effect of cancer on health-related quality of life.

Authors:  D Osoba
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

6.  Measurement of the quality of life in clinical trials: in pursuit of the unapproachable?

Authors:  L Offerhaus
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Aspects of quality of life on treatment with felodipine.

Authors:  E Dimenäs; M A Wallander; K Svärdsudd; I Wiklund
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Cardiff Wound Impact Schedule: the development of a condition-specific questionnaire to assess health-related quality of life in patients with chronic wounds of the lower limb.

Authors:  Patricia Price; Keith Harding
Journal:  Int Wound J       Date:  2004-04       Impact factor: 3.315

9.  Evaluation of three methods of symptom reporting in a clinical trial of felodipine.

Authors:  M A Wallander; E Dimenäs; K Svärdsudd; I Wiklund
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 10.  The potential of biotechnology to improve the quality of life of patients with renal failure.

Authors:  W E Bloembergen; A Laupacis
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.